Soleo Health to distribute new Alzheimer’s treatment
By HME News Staff
Updated 9:32 AM CST, Wed January 11, 2023
FRISCO, Texas – Soleo Health, a national provider of complex specialty pharmacy services, has been selected by Eisai Inc., a developer of pharmaceuticals, as the sole specialty pharmacy distribution partner for LEQEMBI, which was recently approved by the U.S. Food & Drug Administration for the treatment of Alzheimer’s disease. LEQEMBI is an anti-amyloid monoclonal antibody used to treat mild cognitive impairment due to Alzheimer’s and mild or early Alzheimer’s disease (collectively known as early AD). “The selection of Soleo Health as the sole specialty pharmacy distributor for LEQEMBI reflects confidence in our clinical expertise and differentiated patient care model supporting patients in the neurology space,” said Drew Walk, CEO of Soleo Health.” Our partnership with Eisai will afford the Alzheimer’s community continued hope while we assist patients and their caregivers as they navigate their healthcare journey.” Patients receiving LEQEMBI will be supported through Soleo Health’s Alzheimer’s Disease Therapeutic Care Management Center (TCMC), staffed with specially trained interdisciplinary teams comprising highly experienced physician specialists, nurse practitioners, therapy-care pharmacists, registered nurses, reimbursement specialists and patient care ambassadors. Soleo Health’s distinctive Alzheimer’s Disease TCMC is supported through the company’s specialty pharmacy locations nationwide with pharmacy licensure in all 50 states.
Comments